Biobanking market seen reaching $85.77 billion by 2035

Market Research Future projects the global biobanking market will grow from $51.32 billion in 2025 to $85.77 billion by 2035, driven by precision medicine, tighter donor-eligibility rules and expanding cell and gene therapy demand. The report also points to faster growth in Asia-Pacific and rising investment in automation, monitoring and federated data access.

Why it matters: - Biobanking is shifting from simple cold storage to a data-rich infrastructure layer for precision medicine, cell therapy and drug discovery. - The market’s projected rise to $85.77 billion by 2035 signals more spending on validated storage, automation, monitoring and sample-linked data services. - Regulatory clarity and better compliance standards could lower friction for hospital repositories and speed site onboarding.

What happened: - Market Research Future said the global biobanking market will grow from $51.32 billion in 2025 to $85.77 billion by 2035. - The firm put the forecast CAGR at 5.27% for 2025–2035. - The market was estimated at $51.32 billion in 2025, with 2026 valued at $54.02 billion. - The report ties the outlook to precision medicine, multi-omics programs, donor-eligibility guidance and cell-therapy demand.

The details: - Precision medicine programs now want annotated, consented, multi-omics-ready specimens, not just high-volume storage. - Market Research Future estimated that this specification shift lifts revenue per sample by 18% to 22% versus conventional archival storage. - The FDA’s January 2025 draft guidance tightened screening and testing expectations for human cells, tissues and cellular products. - The guidance gives hospital repositories a clearer compliance template and is expected to shorten qualification cycles for new hospital sites by about four months. - More than 2,900 cell and gene therapy trials were active globally in 2025. - Each Phase III program typically requires validated cryopreservation at multiple sites. - Sustained NIH All of Us funding has totaled more than $3.4 billion since inception. - BBMRI-ERIC now connects more than 600 European facilities under harmonized quality standards. - Azenta, Hamilton and Thermo Fisher each committed nine-figure capital programs to automation lines between 2023 and 2025. - North America held 33.4% of 2025 revenue. - Asia-Pacific is projected to grow at 10.40% CAGR through 2035. - Europe held $14.68 billion in 2025 revenue.

Between the lines: - The market’s center of gravity is moving from storage capacity to compliance, metadata, workflow automation and analysis-ready access. - Vendors that can bundle cold chain, software and service are better positioned than pure hardware suppliers. - The report’s regional split suggests mature markets will keep funding large national cohorts, while faster growth will come from emerging genomics programs and hospital-based collection networks. - The strongest economics appear to be in recurring consumables, monitoring and outsourced sample-management services, not just freezers.

What's next: - Market Research Future expects federated access platforms to grow as a revenue layer alongside specimen storage. - The report also sees more demand for AI quality scoring, home-collection workflows and autonomous repository operations by 2032. - India, Indonesia, Saudi Arabia and Brazil are highlighted as markets likely to expand national genomics programs without matching domestic cold-chain capacity. - By 2035, the report expects biobanking to look more like informatics infrastructure than a traditional storage business.

The bottom line: - Biobanking’s next phase is being shaped by precision medicine, stricter donor rules and automation, with the biggest gains likely to come from services wrapped around the sample, not the freezer alone. - More information is available in the full report and a free sample.